Glenmark Pharma share price hits 10% upper circuit on unit's cancer licensing deal with AbbVie

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive licensing agreement between its innovation arm, IGI, and AbbVie for a cancer treatment.

Markets